1. Home
  2. SRPT
  3. SRPT News

Latest Sarepta Therapeutics Inc. (DE) (SRPT) News on March 28, 2025

SRPT

Argus Research

3 days ago

SRPT: What does Argus have to say about SRPT?

How to Play SRPT Stock After Patient Death Post DMD Therapy Infusion
SRPT

Zacks

4 days ago

How to Play SRPT Stock After Patient Death Post DMD Therapy Infusion

Q4 Rundown: Moderna (NASDAQ:MRNA) Vs Other Therapeutics Stocks
SRPT

StockStory

4 days ago

Q4 Rundown: Moderna (NASDAQ:MRNA) Vs Other Therapeutics Stocks

Is This Stock a Buy After a Massive 20% Drop in 1 Day?
SRPT

Motley Fool

5 days ago

Is This Stock a Buy After a Massive 20% Drop in 1 Day?

Q4 Earnings Review: Therapeutics Stocks Led by BioMarin Pharmaceutical (NASDAQ:BMRN)
SRPT

StockStory

7 days ago

Q4 Earnings Review: Therapeutics Stocks Led by BioMarin Pharmaceutical (NASDAQ:BMRN)

The Zacks Analyst Blog Highlights Sarepta Therapeutics, Incyte, Gilead Sciences and VTv Therapeutics
SRPT

Zacks

7 days ago

The Zacks Analyst Blog Highlights Sarepta Therapeutics, Incyte, Gilead Sciences and VTv Therapeutics

Biotech Stock Roundup: Patient Death Hits SRPT, INCY Study Data & More
SRPT

Zacks

8 days ago

Biotech Stock Roundup: Patient Death Hits SRPT, INCY Study Data & More

Strength Seen in Sarepta Therapeutics (SRPT): Can Its 8.7% Jump Turn into More Strength?
SRPT

Zacks

9 days ago

Strength Seen in Sarepta Therapeutics (SRPT): Can Its 8.7% Jump Turn into More Strength?

Why Sarepta Therapeutics Inc. (SRPT) Went Up On Wednesday?
SRPT

Insider Monkey

9 days ago

Why Sarepta Therapeutics Inc. (SRPT) Went Up On Wednesday?

SRPT Nosedives 27% on Patient Death Following DMD Therapy Infusion
SRPT

Zacks

9 days ago

SRPT Nosedives 27% on Patient Death Following DMD Therapy Infusion

Why Sarepta Therapeutics Inc. (SRPT) Crashed On Tuesday?
SRPT

Insider Monkey

9 days ago

Why Sarepta Therapeutics Inc. (SRPT) Crashed On Tuesday?

Company News for Mar 19, 2025
SRPT

Zacks

9 days ago

Company News for Mar 19, 2025

Sarepta's 27% Sell-Off Is 'Overblown,' 'Overdone' And 'Overly Bearish.' Here's Why It Happened.
SRPT

Investor's Business Daily

10 days ago

Sarepta's 27% Sell-Off Is 'Overblown,' 'Overdone' And 'Overly Bearish.' Here's Why It Happened.

SRPT

MT Newswires

10 days ago

Sector Update: Health Care

SRPT

MT Newswires

10 days ago

Sarepta Therapeutics Says Patient Dies After Elevidys Gene Therapy for Duchenne Muscular Dystrophy; Shares Fall

Sarepta Therapeutics Reports Patient Death Post Elevidys Gene Therapy Treatment, Stock Plunges
SRPT

Benzinga

10 days ago

Sarepta Therapeutics Reports Patient Death Post Elevidys Gene Therapy Treatment, Stock Plunges

Sarepta Therapeutics Plummets 23% After Gene Therapy Recipient Dies
SRPT

Investor's Business Daily

10 days ago

Sarepta Therapeutics Plummets 23% After Gene Therapy Recipient Dies

Exploring 3 High Growth Tech Stocks In The US Market
SRPT

Simply Wall St.

21 days ago

Exploring 3 High Growth Tech Stocks In The US Market

Statutory Earnings May Not Be The Best Way To Understand Sarepta Therapeutics' (NASDAQ:SRPT) True Position
SRPT

Simply Wall St.

21 days ago

Statutory Earnings May Not Be The Best Way To Understand Sarepta Therapeutics' (NASDAQ:SRPT) True Position

SRPT

Argus Research

24 days ago

SRPT: Lowering target price to $82.00

Spotting Winners: Sarepta Therapeutics (NASDAQ:SRPT) And Therapeutics Stocks In Q4
SRPT

StockStory

24 days ago

Spotting Winners: Sarepta Therapeutics (NASDAQ:SRPT) And Therapeutics Stocks In Q4

Sarepta price target lowered to $210 from $217 at BofA
SRPT

TipRanks

a month ago

Sarepta price target lowered to $210 from $217 at BofA

Sarepta Therapeutics Announces Call for Applications for the 8th Annual Route 79, The Duchenne Scholarship Program
SRPT

Business Wire

a month ago

Sarepta Therapeutics Announces Call for Applications for the 8th Annual Route 79, The Duchenne Scholarship Program

Sarepta Therapeutics Full Year 2024 Earnings: Revenues Beat Expectations, EPS Lags
SRPT

Simply Wall St.

a month ago

Sarepta Therapeutics Full Year 2024 Earnings: Revenues Beat Expectations, EPS Lags

SRPT

Thomson Reuters StreetEvents

a month ago

Q4 2024 Sarepta Therapeutics Inc Earnings Call

Sarepta Q4 Earnings Lag Estimates, Revenues Gain on Gene Therapy Sales
SRPT

Zacks

a month ago

Sarepta Q4 Earnings Lag Estimates, Revenues Gain on Gene Therapy Sales

SRPT

MT Newswires

a month ago

Deutsche Bank Adjusts Sarepta Therapeutics Price Target to $124 From $136, Maintains Hold Rating

SRPT

MT Newswires

a month ago

RBC Trims Price Target on Sarepta Therapeutics to $161 From $165, Keeps Outperform Rating

SRPT

MT Newswires

a month ago

Morgan Stanley Lifts Price Target on Sarepta Therapeutics to $196 From $195, Keeps Overweight Rating

Sarepta Therapeutics Inc (SRPT) Q4 2024 Earnings Call Highlights: Record Revenue Growth and ...
SRPT

GuruFocus.com

a month ago

Sarepta Therapeutics Inc (SRPT) Q4 2024 Earnings Call Highlights: Record Revenue Growth and ...

Sarepta Therapeutics (SRPT) Q4 2024 Earnings Call Transcript
SRPT

Motley Fool

a month ago

Sarepta Therapeutics (SRPT) Q4 2024 Earnings Call Transcript

Sarepta Therapeutics (SRPT) Lags Q4 Earnings Estimates
SRPT

Zacks

a month ago

Sarepta Therapeutics (SRPT) Lags Q4 Earnings Estimates

SRPT

MT Newswires

a month ago

Sarepta Therapeutics Q4 Non-GAAP Earnings, Revenue Rise

Sarepta Therapeutics, Inc. (SRPT): Among the Stocks That Will Go to The Moon According to Analysts
SRPT

Insider Monkey

a month ago

Sarepta Therapeutics, Inc. (SRPT): Among the Stocks That Will Go to The Moon According to Analysts

Sarepta Therapeutics (SRPT) To Report Earnings Tomorrow: Here Is What To Expect
SRPT

StockStory

a month ago

Sarepta Therapeutics (SRPT) To Report Earnings Tomorrow: Here Is What To Expect

Is Sarepta Therapeutics, Inc. (SRPT) The Best Fast Growth Stock To Buy Right Now?
SRPT

Insider Monkey

a month ago

Is Sarepta Therapeutics, Inc. (SRPT) The Best Fast Growth Stock To Buy Right Now?

SRPT

Argus Research

a month ago

SRPT: Lowering target price to $84.00

Down -8.52% in 4 Weeks, Here's Why Sarepta Therapeutics (SRPT) Looks Ripe for a Turnaround
SRPT

Zacks

a month ago

Down -8.52% in 4 Weeks, Here's Why Sarepta Therapeutics (SRPT) Looks Ripe for a Turnaround

SRPT

MT Newswires

a month ago

Sarepta Therapeutics Closes $600 Million Revolving Credit Facility

Sarepta Therapeutics Announces Inaugural $600 Million Senior Secured Revolving Credit Facility
SRPT

Business Wire

a month ago

Sarepta Therapeutics Announces Inaugural $600 Million Senior Secured Revolving Credit Facility

Sarepta Therapeutics to Announce Fourth Quarter and Full-Year 2024 Financial Results
SRPT

Business Wire

a month ago

Sarepta Therapeutics to Announce Fourth Quarter and Full-Year 2024 Financial Results

SRPT

Thomson Reuters StreetEvents

a month ago

Q1 2025 Arrowhead Pharmaceuticals Inc Earnings Call

SRPT

MT Newswires

a month ago

Deutsche Bank Initiates Coverage on Sarepta Therapeutics With Hold Rating, $136 Price Target

SRPT

MT Newswires

2 months ago

Arrowhead Closes Licensing, Collaboration Agreement With Sarepta

2 Growth Stocks to Buy Hand Over Fist in February
SRPT

Motley Fool

2 months ago

2 Growth Stocks to Buy Hand Over Fist in February

Why Sarepta Therapeutics, Inc. (SRPT) Is Among the Best Healthcare Stocks To Buy According to Analysts
SRPT

Insider Monkey

2 months ago

Why Sarepta Therapeutics, Inc. (SRPT) Is Among the Best Healthcare Stocks To Buy According to Analysts

Nvidia And 2 Other High Growth Tech Stocks In The United States
SRPT

Simply Wall St.

2 months ago

Nvidia And 2 Other High Growth Tech Stocks In The United States

The Zacks Analyst Blog Highlights Amgen, CRISPR, Moderna, Sarepta and Vertex
SRPT

Zacks

2 months ago

The Zacks Analyst Blog Highlights Amgen, CRISPR, Moderna, Sarepta and Vertex

Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Delivered A Weaker ROE Than Its Industry
SRPT

Simply Wall St.

2 months ago

Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Delivered A Weaker ROE Than Its Industry

SRPT

Argus Research

2 months ago

SRPT: Lowering target price to $91.00

Are These 5 Biotech Stocks Set to Beat Q4 Earnings Estimates?
SRPT

Zacks

2 months ago

Are These 5 Biotech Stocks Set to Beat Q4 Earnings Estimates?

Jim Cramer Says ‘I Think Sarepta Therapeutics, Inc. (SRPT) Is A Speculative Situation Where They Have Great Science’
SRPT

Insider Monkey

2 months ago

Jim Cramer Says ‘I Think Sarepta Therapeutics, Inc. (SRPT) Is A Speculative Situation Where They Have Great Science’

Sarepta could be down on patient death in FDA database, says RBC Capital
SRPT

TipRanks

2 months ago

Sarepta could be down on patient death in FDA database, says RBC Capital

SRPT

Argus Research

2 months ago

SRPT: Raising target price to $94.00

SRPT

MT Newswires

2 months ago

Sarepta Therapeutics Says Phase 3 Study of Potential Muscular Dystrophy Drug Shows 'Positive' Results

Sarepta Therapeutics Announces Results from Part 2 of the EMBARK Study Demonstrating Sustained Benefits and Disease Stabilization in Ambulatory Individuals with Duchenne Muscular Dystrophy Following Treatment with ELEVIDYS
SRPT

Business Wire

2 months ago

Sarepta Therapeutics Announces Results from Part 2 of the EMBARK Study Demonstrating Sustained Benefits and Disease Stabilization in Ambulatory Individuals with Duchenne Muscular Dystrophy Following Treatment with ELEVIDYS

SRPT

Argus Research

2 months ago

SRPT: Lowering target price to $93.00

Sarepta Therapeutics, Inc. (SRPT): A Bull Case Theory
SRPT

Insider Monkey

2 months ago

Sarepta Therapeutics, Inc. (SRPT): A Bull Case Theory

SRPT

Argus Research

2 months ago

SRPT: Lowering target price to $95.00

Sarepta Therapeutics Reports Preliminary* Fourth Quarter and Full-Year 2024 Net Product Revenue
SRPT

Business Wire

2 months ago

Sarepta Therapeutics Reports Preliminary* Fourth Quarter and Full-Year 2024 Net Product Revenue

SRPT

MT Newswires

3 months ago

RBC Cuts Price Target on Sarepta Therapeutics to $165 From $182, Keeps Outperform Rating

Sarepta Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference
SRPT

Business Wire

3 months ago

Sarepta Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference

SRPT Stock Rises 23% in a Year: Time to Buy, Hold or Sell?
SRPT

Zacks

3 months ago

SRPT Stock Rises 23% in a Year: Time to Buy, Hold or Sell?

Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SRPT

Business Wire

3 months ago

Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Sarepta Therapeutics, Inc. (SRPT): Is This Gene Therapy Stock a Good Buy Right Now?
SRPT

Insider Monkey

3 months ago

Sarepta Therapeutics, Inc. (SRPT): Is This Gene Therapy Stock a Good Buy Right Now?

Exploring High Growth Tech Stocks in the US December 2024
SRPT

Simply Wall St.

3 months ago

Exploring High Growth Tech Stocks in the US December 2024

SRPT

Argus Research

3 months ago

SRPT: Lowering target price to $97.00

Is Sarepta Therapeutics, Inc. (SRPT) the Best Performing Biotech Stock in 2024?
SRPT

Insider Monkey

3 months ago

Is Sarepta Therapeutics, Inc. (SRPT) the Best Performing Biotech Stock in 2024?

The Zacks Analyst Blog Highlights Sarepta Therapeutics, ADMA Biologics, Exelixis and Alnylam
SRPT

Zacks

3 months ago

The Zacks Analyst Blog Highlights Sarepta Therapeutics, ADMA Biologics, Exelixis and Alnylam

4 Biotech Stocks Most Wall Street Analysts Are Bullish About
SRPT

Zacks

3 months ago

4 Biotech Stocks Most Wall Street Analysts Are Bullish About

Sarepta completes subject dosing in Phase III LGMD2E/R4 therapy trial
SRPT

Clinical Trials Arena

3 months ago

Sarepta completes subject dosing in Phase III LGMD2E/R4 therapy trial

SRPT Finishes Enrolment in Late-Stage Study for Rare Muscular Disorder
SRPT

Zacks

3 months ago

SRPT Finishes Enrolment in Late-Stage Study for Rare Muscular Disorder

Sarepta Therapeutics Completes Enrollment in EMERGENE, a Phase 3 Clinical Study of SRP-9003 for the Treatment of Limb-Girdle Muscular Dystrophy Type 2E/R4
SRPT

Business Wire

3 months ago

Sarepta Therapeutics Completes Enrollment in EMERGENE, a Phase 3 Clinical Study of SRP-9003 for the Treatment of Limb-Girdle Muscular Dystrophy Type 2E/R4

Tessera gets sickle cell funding; Corvus shares slide on eczema data
SRPT

BioPharma Dive

3 months ago

Tessera gets sickle cell funding; Corvus shares slide on eczema data

SRPT

Argus Research

3 months ago

SRPT: What does Argus have to say about SRPT?

3 Biotech Stocks With Promising Gene Therapies to Watch Out in 2025
SRPT

Zacks

3 months ago

3 Biotech Stocks With Promising Gene Therapies to Watch Out in 2025

SRPT

MT Newswires

3 months ago

Sarepta Therapeutics Insider Sold Shares Worth $1,310,820, According to a Recent SEC Filing

Sarepta Therapeutics, Inc. (SRPT): A Bull Case Theory
SRPT

Insider Monkey

3 months ago

Sarepta Therapeutics, Inc. (SRPT): A Bull Case Theory

Wall Street Analysts See a 47.95% Upside in Sarepta Therapeutics (SRPT): Can the Stock Really Move This High?
SRPT

Zacks

4 months ago

Wall Street Analysts See a 47.95% Upside in Sarepta Therapeutics (SRPT): Can the Stock Really Move This High?

SRPT

Argus Research

4 months ago

SRPT: What does Argus have to say about SRPT?

Why Is Sarepta Therapeutics (SRPT) Up 4.9% Since Last Earnings Report?
SRPT

Zacks

4 months ago

Why Is Sarepta Therapeutics (SRPT) Up 4.9% Since Last Earnings Report?

SRPT

Argus Research

4 months ago

SRPT: Lowering target price to $101.00

SRPT

Zacks Small Cap Research

4 months ago

ARWR: License and Collaboration Deal with Sarepta Includes $825 Million Upon Closing…

Arrowhead price target lowered to $24 from $27 at Bernstein
SRPT

TipRanks

4 months ago

Arrowhead price target lowered to $24 from $27 at Bernstein

Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SRPT

Business Wire

4 months ago

Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Sarepta Therapeutics Stock Surges 43% YTD: How to Play the Stock?
SRPT

Zacks

4 months ago

Sarepta Therapeutics Stock Surges 43% YTD: How to Play the Stock?

Sarepta price target lowered to $202 from $205 at Needham
SRPT

TipRanks

4 months ago

Sarepta price target lowered to $202 from $205 at Needham

SRPT Inks $11B Licensing Deal With Arrowhead for Rare Gene Therapies
SRPT

Zacks

4 months ago

SRPT Inks $11B Licensing Deal With Arrowhead for Rare Gene Therapies

Wall Street Analysts Think Sarepta Therapeutics (SRPT) Could Surge 42.11%: Read This Before Placing a Bet
SRPT

Zacks

4 months ago

Wall Street Analysts Think Sarepta Therapeutics (SRPT) Could Surge 42.11%: Read This Before Placing a Bet

Sarepta to pay Arrowhead $500M + in licensing deal for siRNA-based treatments
SRPT

TipRanks

4 months ago

Sarepta to pay Arrowhead $500M + in licensing deal for siRNA-based treatments

Arrowhead to get $825M in Sarepta licensing pact, appoints Sarepta CEO to board
SRPT

TipRanks

4 months ago

Arrowhead to get $825M in Sarepta licensing pact, appoints Sarepta CEO to board

Sarepta rebuilds drug pipeline with Arrowhead deal
SRPT

BioPharma Dive

4 months ago

Sarepta rebuilds drug pipeline with Arrowhead deal

Arrowhead and Sarepta link for rare genetic disease treatments
SRPT

Pharmaceutical Technology

4 months ago

Arrowhead and Sarepta link for rare genetic disease treatments

SRPT

Argus Research

4 months ago

SRPT: Raising target price to $104.00

Arrowhead Pharma, Sarepta TX ink new gene therapy deal
SRPT

Yahoo Finance Video

4 months ago

Arrowhead Pharma, Sarepta TX ink new gene therapy deal

SRPT

MT Newswires

4 months ago

Sector Update: Health Care

Arrowhead, Sarepta Skyrocket After Duo Inks A Whopping $11.38 Billion Deal
SRPT

Investor's Business Daily

4 months ago

Arrowhead, Sarepta Skyrocket After Duo Inks A Whopping $11.38 Billion Deal

Arrowhead Launches 25% On A Massive Licensing Deal With Sarepta
SRPT

Investor's Business Daily

4 months ago

Arrowhead Launches 25% On A Massive Licensing Deal With Sarepta

SRPT

MT Newswires

4 months ago

Arrowhead Pharma, Sarepta Therapeutics Sign Licensing, Partnership Deal for Clinical, Preclinical Programs

Sarepta Therapeutics Announces Global Licensing and Collaboration Agreement with Arrowhead Pharmaceuticals for Multiple Clinical and Preclinical siRNA Programs
SRPT

Business Wire

4 months ago

Sarepta Therapeutics Announces Global Licensing and Collaboration Agreement with Arrowhead Pharmaceuticals for Multiple Clinical and Preclinical siRNA Programs

Share on Social Networks: